Univercells

OverviewSuggest Edit

Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end"​ solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.

Univercells'​ technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based on single-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture.

Univercells positions itself as a global partner for developing biomanufacturing/biosimilar solution, going from the process design, to the selection of the best technologies (USP, DSP, filing technologies, etc), to the design of the clinical plan, the process development, the technology transfer, the facility construction or the training of the staff.

TypePrivate
Founded2013
HQCharleroi, BE
Websiteunivercells.com

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2020)152(+6%)

Key People/Management at Univercells

Hugues Bultot

Hugues Bultot

Chief Executive Officer, Co-Founder
Vincent Vanderborght

Vincent Vanderborght

CFO
Cécile Jacoby

Cécile Jacoby

Chief Project Officer
Christian Borgniet

Christian Borgniet

COO
David Louvet

David Louvet

Chief Human Resources Officer
David Shofi

David Shofi

Chief Legal Officer
Show more

Univercells Office Locations

Univercells has offices in Charleroi, Nivelles and Woluwe-Saint-Pierre
Charleroi, BE (HQ)
Rue Auguste Piccard 48
Nivelles, BE
Rue de la Maîtrise 11
Woluwe-Saint-Pierre, BE
Avenue de Tervueren 270
Show all (3)

Univercells Financials and Metrics

Summary Metrics

Founding Date

2013

Univercells total Funding

$37.7 m

Univercells latest funding size

$18.80 m

Time since last funding

2 years ago

Univercells investors

Univercells's latest funding round in July 2018 was reported to be $18.8 m. In total, Univercells has raised $37.7 m
Show all financial metrics

Univercells Online and Social Media Presence

Embed Graph

Univercells News and Updates

Univercells nets $3.56 mln Series A

Univercells, a Belgian provider of biomanufacturing solutions, has raised $3.56 million in Series A funding. The investors included Takeda Ventures Inc.

Univercells Blogs

Protected: Promising Vero cell growth in scale-X™ bioreactors

There is no excerpt because this is a protected post. The post Protected: Promising Vero cell growth in scale-X™ bioreactors appeared first on Univercells.

COVID-19 update: A word from our CEO to our partners & customers

In light of the current situation and unprecedented Coronavirus pandemic (COVID-19), Univercells is more than ever committed to deliver on its mission to make biologics available and affordable to all and participate in improving global health. The post COVID-19 update: A word from our CEO to our pa…

Univercells launches CDMO Exothera with GMP capabilities in 15,000m² site in Jumet, Belgium

Exothera will partner with cell & gene therapy innovators to unlock their manufacturing potential by capitalizing on best-in-class manufacturing technologies and bioprocessing expertise. The post Univercells launches CDMO Exothera with GMP capabilities in 15,000m² site in Jumet, Belgium appeared…

Univercells secures up to €50M investment from KKR platform to speed delivery of manufacturing technologies

Univercells has announced up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment firm KKR The post Univercells secures up to €50M investment from KKR platform to speed delivery of manufacturing technologies appeared first on Univercells.

Univercells boosted by EUR 20M European financing to accelerate the delivery of its vaccine portfolio

Financing will support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes The post Univercells boosted by EUR 20M European financing to accelerate the delivery of its vaccine portfoli…

Univercells expands its development capacity with modular laboratories

400 m² extension will enable the company to pursue the development of its viral vaccines' portfolio addressing global health challenges The post Univercells expands its development capacity with modular laboratories appeared first on Univercells.
Show more

Univercells Frequently Asked Questions

  • When was Univercells founded?

    Univercells was founded in 2013.

  • Who are Univercells key executives?

    Univercells's key executives are Hugues Bultot, Vincent Vanderborght and Cécile Jacoby.

  • How many employees does Univercells have?

    Univercells has 152 employees.

  • Who are Univercells competitors?

    Competitors of Univercells include Centrexion, Principia BioPharma and Rapid Micro Biosystems.

  • Where is Univercells headquarters?

    Univercells headquarters is located at Rue Auguste Piccard 48, Charleroi.

  • Where are Univercells offices?

    Univercells has offices in Charleroi, Nivelles and Woluwe-Saint-Pierre.

  • How many offices does Univercells have?

    Univercells has 3 offices.